COLLEGIUM PHARMACEUTICAL, INC 8-K/A

What Happened Collegium Pharmaceutical (COLL) filed an 8-K on June 30, 2026 (Item 9.01) disclosing that the reported consolidated financial statements relate to Corium and include discussion of AZSTARYS and ADLARITY. The filing states that AZSTARYS constituted substantially all of Corium’s consolidated operations, and that ADLARITY — an FDA‑approved Alzheimer’s product — was not part of the Acquisition and was not acquired by Collegium. Corium’s consolidated financial statements are presented pursuant to Rule 3‑05 of Regulation S‑X, and the filing also includes unaudited pro forma financial information.

Key Details

• Filing date: June 30, 2026 (Form 8‑K, Item 9.01).
• AZSTARYS represented substantially all of Corium’s consolidated operations.
• ADLARITY (FDA‑approved Alzheimer’s product) was not part of the Acquisition and was not acquired.
• Corium’s consolidated statements are presented under Rule 3‑05 of Regulation S‑X; unaudited pro forma financial information is included in the filing.

Why It Matters This filing clarifies which Corium assets and results are being reflected in the reported financials and pro forma metrics. For investors, the key points are that AZSTARYS is the primary business contributing to Corium’s results and that ADLARITY is explicitly excluded from the acquisition and not being actively commercialized by the seller — meaning any expected revenue or liabilities tied to ADLARITY are not part of Collegium’s purchase. The Rule 3‑05 presentation and the included pro forma information help investors see the acquired company’s standalone financials and how the acquisition may affect Collegium’s reported results.